| Ticker: | ARQL | 200 Boston Avenue | |
| Exchange: | NASDAQ-National Market | Medford, Massachusetts 02155 | |
| Industry: | Manufacturing | (617) 395-4100 |
| Type of Shares: | Common Shares | Filing Date: | 8/29/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 10/16/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $30,000,000 | Selling: | $0.48 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,476,487 |
| Manager | Tier | Phone |
| Hambrecht & Quist Incorporated | Lead Manager | (415) 576-3423 |
| Oppenheimer & Company, Inc. | Co-manager | (212) 667-7402 |
| Vector Securities International, Inc. | Co-manager | (708) 940-1970 |
| Auditor: Price Waterhouse | |||||
| 6 Month Ending Financials | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $3.33 | $2.98 | $1.52 | Assets: | $11.85 |
| Net Income: | -$2.25 | -$0.75 | -$1.07 | Liabilities: | $6.57 |
| EPS: | -$0.33 | -$0.10 | Equity: | $5.28 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company has created a new technology platform for the discovery and production of novel chemical compounds that have commercial potential. ArQule provides these compounds to members of the pharmaceutical and biotechnology industries. The company has developed a proprietary modular building block technology that it has integrated with structure-guided drug design, high speed parallel chemical synthesis and information technology to identify and optimize drug development candidates. To date, the company has entered into collaborative arrangements with Pharmacia Biotech AB, Abbott Laboratories and Solvay Duphar B.V., and has formed joint discovery programs with several biotechnology companies. ArQule believes that its technology will allow its collaborative partners to accelerate the drug discovery process by several years, permitting them to realize significant cost reductions and the earlier recovery of research and development expenditures for successful drugs. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund research and product development programs and for working capital and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.